Overview

Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-alpha Blocker

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active rheumatoid arthritis in patients who have failed treatment with Methotrexate and at least one TNF-alpha blocking agent.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Emergent Product Development Seattle LLC
Treatments:
Antibodies, Monoclonal
Methotrexate
Zanolimumab